Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982284033> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2982284033 endingPage "S576" @default.
- W2982284033 startingPage "S576" @default.
- W2982284033 abstract "Lung cancer remained one of the deadest cancers throughout worldwide. ALTER0303 trial revealed anlotinib might be used as a third-line or further treatment in non-small-cell lung cancer patients. While previous therapy strategy would have impact on efficiency of anlotinib still remained unknown. The subgroup of patients in ALTER0303 were analyzed by using Kaplan-meier estimates, Pearson X2 or Fisher exact test. There is no statistical significance on progression-free survival (PFS) and overall survival (OS) among patients in different previous antiangiogenic treatments groups. Patients in the chest radiotherapy (CRT) group had longer median PFS than non-CRT group (5.93m vs. 4.63m, P=0.027). No matter what kind of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) and chemotherapy regimens used previously, all patients gained longer PFS from anlotinib. While only patients treated with vinorelbine/platinum in EGFR wild type group, pemetrexed/platinum, vinorelbine/platinum and gefitinibin in EGFR mutation group, EGFR TKI used as the first line group could benefit from anlotinib on OS. When the OS was calculated from the time of diagnosis to death, anlotinib may improve about 6 months median OS (33.8m vs.27.8m, P<0.001) compared to placebo with HR (95%CI): 0.77 (0.60, 1.00).View Large Image Figure ViewerDownload Hi-res image Download (PPT) This study indicated previous bevacizumab or endostatin treatments had no impact on the efficiency of anlotinib. Patients with CRT history benefited more from anlotinib on PFS. EGFR TKI and chemotherapy treatments history had more impact on OS than PFS in patients treated with anlotinib compare to placebo." @default.
- W2982284033 created "2019-11-01" @default.
- W2982284033 creator A5068922999 @default.
- W2982284033 creator A5087802757 @default.
- W2982284033 creator A5090620338 @default.
- W2982284033 date "2019-10-01" @default.
- W2982284033 modified "2023-10-04" @default.
- W2982284033 title "P1.14-54 Previous Therapy Strategy Impact on Efficiency of Anlotinib Hydrochloride as 3rd Line Treatment: A Subgroup Analysis of ALTER0303 Trial" @default.
- W2982284033 doi "https://doi.org/10.1016/j.jtho.2019.08.1205" @default.
- W2982284033 hasPublicationYear "2019" @default.
- W2982284033 type Work @default.
- W2982284033 sameAs 2982284033 @default.
- W2982284033 citedByCount "0" @default.
- W2982284033 crossrefType "journal-article" @default.
- W2982284033 hasAuthorship W2982284033A5068922999 @default.
- W2982284033 hasAuthorship W2982284033A5087802757 @default.
- W2982284033 hasAuthorship W2982284033A5090620338 @default.
- W2982284033 hasBestOaLocation W29822840331 @default.
- W2982284033 hasConcept C126322002 @default.
- W2982284033 hasConcept C143998085 @default.
- W2982284033 hasConcept C2776256026 @default.
- W2982284033 hasConcept C2776694085 @default.
- W2982284033 hasConcept C2777240266 @default.
- W2982284033 hasConcept C2777802072 @default.
- W2982284033 hasConcept C2778239845 @default.
- W2982284033 hasConcept C2780350996 @default.
- W2982284033 hasConcept C2780739268 @default.
- W2982284033 hasConcept C71924100 @default.
- W2982284033 hasConceptScore W2982284033C126322002 @default.
- W2982284033 hasConceptScore W2982284033C143998085 @default.
- W2982284033 hasConceptScore W2982284033C2776256026 @default.
- W2982284033 hasConceptScore W2982284033C2776694085 @default.
- W2982284033 hasConceptScore W2982284033C2777240266 @default.
- W2982284033 hasConceptScore W2982284033C2777802072 @default.
- W2982284033 hasConceptScore W2982284033C2778239845 @default.
- W2982284033 hasConceptScore W2982284033C2780350996 @default.
- W2982284033 hasConceptScore W2982284033C2780739268 @default.
- W2982284033 hasConceptScore W2982284033C71924100 @default.
- W2982284033 hasIssue "10" @default.
- W2982284033 hasLocation W29822840331 @default.
- W2982284033 hasOpenAccess W2982284033 @default.
- W2982284033 hasPrimaryLocation W29822840331 @default.
- W2982284033 hasRelatedWork W2093810498 @default.
- W2982284033 hasRelatedWork W2128997119 @default.
- W2982284033 hasRelatedWork W2161557607 @default.
- W2982284033 hasRelatedWork W2358450743 @default.
- W2982284033 hasRelatedWork W2404692521 @default.
- W2982284033 hasRelatedWork W2569260518 @default.
- W2982284033 hasRelatedWork W3029430426 @default.
- W2982284033 hasRelatedWork W3206914879 @default.
- W2982284033 hasRelatedWork W4256013750 @default.
- W2982284033 hasRelatedWork W49755809 @default.
- W2982284033 hasVolume "14" @default.
- W2982284033 isParatext "false" @default.
- W2982284033 isRetracted "false" @default.
- W2982284033 magId "2982284033" @default.
- W2982284033 workType "article" @default.